Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.

Employees

903

Sector

Medical Equipment, Supplies & Distribution

Calendar

04-25 - Earnings release - Annual 2025

More about the company

Quotes

Date	Price	Change	Volume
13/03/26	124.14 ¥	-3.02%	2,076,597
12/03/26	128.00 ¥	-6.23%	2,550,437
11/03/26	136.50 ¥	+0.21%	1,373,190
10/03/26	136.21 ¥	+2.80%	1,351,723
09/03/26	132.50 ¥	-1.12%	1,301,724

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 13/03/2026			5-day change	1st Jan Change
124.14 ^CNY	-3.02%		-7.36%	-23.37%

03-11	Beijing Hotgen Biotech Subsidiary Doses First Patient in Phase 2 Trial for Heart Attack Drug	MT
02-27	Hotgen Biotech's Loss Widens in 2025	MT

Capitalization	14.39B 2.09B 1.83B 1.65B 1.58B 2.86B 193B 2.98B 19.76B 7.82B 92.35B 7.83B 7.67B 333B	P/E ratio 2023	132x	P/E ratio 2024	-29.9x
Enterprise value	13.32B 1.93B 1.69B 1.53B 1.46B 2.65B 179B 2.76B 18.29B 7.23B 85.47B 7.25B 7.09B 308B	EV / Sales 2023	5.7x	EV / Sales 2024	8.74x
Free-Float	63.02%	Yield 2023	0.49%	Yield 2024	-

03-11	Beijing Hotgen Biotech Subsidiary Doses First Patient in Phase 2 Trial for Heart Attack Drug	MT
02-27	Hotgen Biotech's Loss Widens in 2025	MT
02-26	Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-05	Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on November 11, 2025.	CI
12-16	Beijing Yaojing Gene Technology Co., Ltd announced that it expects to receive funding from Beijing Hotgen Biotech Co., Ltd.	CI
12-16	Beijing Hotgen Biotech Co., Ltd. signed a letter of intent to acquire an additional unknown minority stake in Beijing Shunjing Biomedical Technology Co., Ltd.	CI
11-11	Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	CI
11-10	Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.	CI
23/10/25	Beijing Hotgen Biotech Q3 net loss at 25.0 million yuan	RE
23/10/25	Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
21/09/25	Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index	CI
04/09/25	Hotgen Biotech Gets Five Medical Device Certificates	MT
29/08/25	Beijing Hotgen Biotech H1 net loss 84.0 million yuan	RE

1 day	-3.02%
1 week	-7.36%
Current month	-2.02%
1 month	-9.22%
3 months	-38.42%
6 months	-35.69%
Current year	-23.37%

Beijing Hotgen Biotech Co., Ltd. Share Price

Equities

688068

CNE100003P82

Medical Equipment, Supplies & Distribution

Valuation: Beijing Hotgen Biotech Co., Ltd.

Chart: Beijing Hotgen Biotech Co., Ltd.

Latest news: Beijing Hotgen Biotech Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Beijing Hotgen Biotech Co., Ltd.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	123.8	139.33
1 month	120.58	139.33
Current year	120.58	214.78
1 year	78.32	262.22
3 years	22.94	262.22
5 years	22.94	262.22
10 years	22.94	262.22

Manager	Title	Age	Since
Chang Qing Lin CEO	Chief Executive Officer	50	31/03/2006
Jianguo Chen PRN	Corporate Officer/Principal	-	03/07/2025
Yong Zhan Shi DFI	Director of Finance/CFO	44	31/01/2015

Director	Title	Age	Since
Xiao Ge Xu BRD	Director/Board Member	55	03/07/2022
Chang Qing Lin CHM	Chairman	50	31/01/2014
Yun Feng Song BRD	Director/Board Member	56	30/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BEIJING HOTGEN BIOTECH CO., LTD.	-3.02%	-7.36%	+49.14%	+143.89%	1.6B
BIOMÉRIEUX	+0.74%	-0.37%	-16.91%	-0.33%	12.84B
GUARDANT HEALTH, INC.	+1.75%	-6.26%	+99.32%	+220.31%	11.21B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-2.24%	-3.69%	-11.82%	-11.62%	5.98B
LANTHEUS HOLDINGS, INC.	-1.16%	+9.55%	-21.37%	+8.86%	5.14B
CARIS LIFE SCIENCES, INC.	+2.60%	-2.37%	-	-	5.13B
DIASORIN S.P.A.	-1.20%	-7.19%	-32.94%	-40.58%	3.95B
ANDON HEALTH CO., LTD.	-6.06%	+12.79%	+30.36%	+23.32%	3.37B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.26%	-0.46%	-17.79%	-42.93%	2.89B
10X GENOMICS, INC.	-0.79%	-9.71%	+81.72%	-61.39%	2.4B
Average	-0.96%	-1.47%	+17.74%	+26.61%	5.45B
Weighted average by Cap.	-0.17%	-1.42%	+18.47%	+46.98%

	2023	2024
Net sales	541M 78.49M 68.76M 62.1M 59.35M 108M 7.26B 112M 743M 294M 3.47B 295M 288M 12.52B	511M 74.09M 64.9M 58.61M 56.03M 102M 6.85B 106M 702M 277M 3.28B 278M 272M 11.82B
Net income	27.38M 3.97M 3.48M 3.14M 3M 5.45M 367M 5.67M 37.61M 14.87M 176M 14.9M 14.59M 633M	-191M -27.7M -24.26M -21.91M -20.95M -37.99M -2.56B -39.58M -262M -104M -1.23B -104M -102M -4.42B
Net Debt	-587M -85.18M -74.61M -67.39M -64.41M -117M -7.88B -122M -807M -319M -3.77B -320M -313M -13.59B	-1.07B -156M -136M -123M -118M -213M -14.39B -222M -1.47B -582M -6.88B -584M -571M -24.81B